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Background. Cilazapril is a novel angiotensin converting enzyme inhibitor with antiproliferative effects in the rat model after balloon injury.
Methods and Results. We conducted a randomized, double-blind placebo-controlled trial to assess the effect of cilazapril in angiographic restenosis prevention after percutaneous transluminal coronary angioplasty (PTCA) . Patients received cilazapril 2.5 mg in the evening after successful PTCA and 5 mg b.l.d. for 6 months or matched placebo. In addition, all patients received aspirin for 6 months. Coronary angiograms before PTCA, after PTCA, and at 6-month follow-up were quantitatively analyzed. In 94% of 735 recruited patients, PICA was successful and all inclusion and exclusion criteria were met. For the per-protocol analysis, quantitative angiography after PTCA and at follow-up was available in 595 patients who complied with the treatment regimen (309 control, 286 cilazapril). The mean difference in minimal coronary lumen diameter between post-PTCA and follow-up angiogram (primary end point) was -0.29:t0A9 mm in the control group and -0.27±0.51 mm in the cilazapril group. Clinical events during 6-month follow-up, analyzed on an intention-to-treat basis, were ranked according to the most serious clinical event ranging from death (control, two; cilazapril, three), nonfatal myocardial infarction (control, eight; cilazapril, 5) , coronary revascularization (control, 51; cilazapril, 53), or recurrent angina requiring medical therapy (control, 67; cilazapril, 68) to none of the above (control, 224; cilazapril, 212). There were no significant differences in ranking.
Conclusions. Long-term angiotensin converting enzyme For the purpose of the study, three coronary angiograms were obtained in each patient -one just before PTCA, one immediately after PTCA, and one at followup. Angiograms were recorded in such a way that they were suitable for quantitative analysis by the Coronary Angiography Analysis System (CAAS). An example of an analysis is shown in Figure 2 . To standardize the method of data acquisition and to ensure exact reproducibility of post-PTCA and follow-up angiograms, measures were taken as described earlier.21,33 All angiographic analyses, including qualitative assessment of certain lesion characteristics,34-36 were performed at a core laboratory, which was blinded to treatment allocation and did not have access to clinical data.
As visual assessment of coronary angiograms is hampered by a large interobserver and intraobserver variability,33'37 all cineangiograms were quantitatively analyzed using the CAAS system, which has been validated and described in detail. 3338 The absolute values of the stenosis diameter as well as the reference diameter are measured by the computer, using the known contrastempty catheter diameter as a scaling device. To achieve maximal vasodilatation, intracoronary nitroglycerin or isosorbide dinitrate was given for each coronary artery involved before PTCA, after PTCA, and at follow-up angiography. All contour positions of the catheter and the arterial segment were corrected for pincushion distortion introduced by the individual image intensifiers. Because the algorithm is not able to measure total occlusions and lesions with TIMI-1 perfusion, a value of 0 mm was used for the minimal lumen diameter and 100% for the percent diameter stenosis. In these cases, the post-PTCA reference diameter was used as the reference diameter before PTCA or at follow-up.
End Points
The primary end point of this study was the withinpatient change in minimal lumen diameter as deterat SWETS SUBS SERVICE on February 3, 2010 circ.ahajournals.org Downloaded from mined by quantitative angiography after PTCA and at follow-up. Post-PTCA values were obtained from the last post-PTCA angiogram made directly after removal of the guide wire. The initial procedure was considered finished when the guide catheter was removed. In the case that the clinical condition required repeat PTCA, the angiogram made before repeat PTCA was used to obtain follow-up values irrespective of the timing of repeat PTCA (hours, days, or weeks).
For each dilated segment, the minimal lumen diameter was taken as the mean value from multiple matched projections. Within-patient change was defined as the follow-up value minus the post-PTCA value. In the case that more than one segment was dilated (multivessel or multisite procedures), the mean change over all lesions dilated was taken as the end point. Secondary end points were restenosis rates, exercise test results, and clinical events. These were death (irrespective of cause), New York Heart Association class Ill-IV as a result of congestive heart failure, nonfatal myocardial infarction (symptoms, ECG changes, and creatine kinase enzymes above twice the upper limit of normal), coronary revascularization (CABG, repeat PTCA, stent implantation, or atherectomy at the same site or other site), and recurrent angina requiring initiation or increase in medical therapy, or none of the above. Only revascularizations that were done before the 6-month time window (6 months+3 weeks) were counted as a clinical event.
Statistical Methods and Analysis
As stated in the original protocol, the required sample size (200 evaluable patients per treatment group) was based on the assumption of a restenosis rate of 30% in the control group and of 15% (i.e., a 50% difference) in the cilazapril group (two-sided test with an a error of 0.05 and a power of 0.80). However To test the hypothesis that the mean change in minimal lumen diameter is equal in the two treatment groups, ANOVA was done with treatment and center as main factors and treatment times center as interaction term. As the change in minimal luminal diameter after PTCA follows a near-gaussian distribution, parametric tests were allowed to be used. 39 The treatment effect was defined as the difference in mean change in minimal lumen diameter between the two treatment groups. In addition, 95% confidence intervals of the treatment effect were obtained from the ANOVA.
Comparison of the clinical outcome was done for the intention-to-treat population. Each patient was assigned at the time of follow-up to the most serious applicable event on the scale described above. For comparison of the clinical outcome between the two treatment groups, standard nonparametric statistical methods were used.
Results
In total, 735 patients gave informed consent, and subsequently, 693 continued the trial and constituted the intention-to-treat population. Figure 1 shows the patient flowchart. Forty-two patients (23 patients randomly assigned to cilazapril and 19 patients to placebo) were not included in the trial for the following reasons. In four patients, no PTCA was performed because the lesion was no longer an indication for PTCA; in 25 patients, the outcome of the PTCA procedure was unsatisfactory (two patients with a post-PTCA diameter stenosis of >50% by visual assessment), unsuccessful (11 patients because of inability to cross the lesion), or complicated (four patients with emergency CABG, eight patients with sustained occlusion). Thirteen patients were excluded from the analysis (10 because a selection criterion was overlooked, three because no baseline quantitative analysis was possible). Of Controlled by nitrates (i.v.) 28 15 Controlled by maximal medication 11 16 Continues at maximal medication 2 More recently, several groups have studied the effects of angiotensin II on smooth muscle cell proliferation in vitro as well as the influence of ACE inhibition on smooth muscle cell proliferation. Angiotensin II induced expression of several growth factor genes, such as genes encoding PDGF, transforming growth factor-p (TGF-f3), and thrombospondin (TS).43-46 These results demonstrate that, in cultured cells, angiotensin II induces messenger ribonucleic acids to encode several important growth factor genes and thus induces cell proliferation. Cilazapril or its active metabolite did not have a direct effect by itself, but the antiproliferative effect was mediated through angiotensin II. Consequently, the inhibition of angiotensin II production may prevent the proliferative response that occurs after PTCA in humans.
Trial Design: Quantitative Angiography as Primary End Point
The primary goal of a restenosis prevention trial is the improvement in short-term and long-term clinical outcome of patients having undergone a PTCA procedure. It is assumed that the improvement in clinical outcome is related to an anatomical phenomenon, namely, the prevention of the recurrence of the stenosis in the treated vessel. However, in trials testing pharmacological compound with possible anti-ischemic or antianginal effects unrelated to the postinjury hyperplasia, the clinical outcome might be misleading and obscure the reason for the observed improvement. Quantification of luminal dimension changes over time may provide insight into the biological and mechanistic effects on the treatment after PTCA. The appearance (or reappearance) of angina as a sole criterion of restenosis underestimates the angiographic rate of restenosis. The poor value of recurrent anginal symptoms as a marker of restenosis is confirmed by the low predictive value of symptoms found in many studies.'8 Similarly, the usefulness of ergometry to detect restenosis after PTCA has been questioned since several studies have found that the presence of exercise test-induced angina or ST segment depression/elevation or both are not highly predictive for restenosis when the test is performed early or late after PTCA.18 A drug tested for its ability to prevent restenosis may be shown to be beneficial after PTCA by reducing angina during exercise testing and yet have no effect on intimal hyperplasia after balloon-induced injury.
In the present study, fewer patients in the cilazapriltreated group experienced anginal pain during exercise testing. This symptomatic beneficial effect was not corroborated by an increase in work load or in double product or by ST changes. It must be emphasized that this difference in behavior between the two groups remains unexplained and had no bearing on the general outcome of the trial. In contradistinction, the prognostic value of the change in sequential coronary angiogram has been largely underestimated as a surrogate end point for clinical atherosclerotic events. In the second phase of the pharmacological investigation, the main emphasis should be put on the pathophysiological mechanism of prevention of restenosis in the postinjury model, and the improvement in clinical outcome should be viewed as a secondary benefit dependent on the anatomical status.
When the patient population of this trial is stratified according to the minimal lumen values at follow-up, it appears that the percentage of patients having reached one of the predefined clinical end points is as high as 65% in the worst category (minimal lumen diameter at follow-up <1.10 mm), whereas the percentage of eventfree patients ranges from 63% to 78% in the other categories (Table 8) . It The dose selected for this trial was based on pharmacokinetic data in healthy volunteers, demonstrating that a single dose of 5 mg cilazapril reduced the plasma ACE activity to virtually unmeasurable levels.4849 Pharmacokinetic data from hypertensive patients demonstrate that after a single dose of 5 mg cilazapril, the plasma angiotensin II concentration starts to return to baseline in 8-10 hours, although a sustained blood pressure reduction is achieved. Therefore, the dosage of 5 mg After the trial was designed, it was shown that inhibition of neointima formation is a dose-dependent phenomenon and that the dose required for inhibition of neointimal formation appears to be somewhat higher than for lowering blood pressure. 46 In the rat model, this dose relation for the antiproliferative effect of cilazapril is different from the dose relation for the antihypertensive effect. Thus, a possible explanation for the lack of effect in MERCATOR is that the dose used was too low, as the dose used in the rat model was 70 times higher (10 mg/kg/day). The ongoing American/Canadian sister trial to MERCATOR, MARCATOR, which is similar in design but randomizes between 1, 5, and 10 mg of cilazapril b.i.d., will give us the unique opportunity to further investigate this relation in humans. If the antihypertensive effect in the 10 mg-b.i.d. subset of patients does not materially differ from that in the two other arms of the trial (1 and 5 mg b.i.d.) , although a direct antiproliferative effect is observed, further investigation of the role of the renin-angiotensin system in tissue proliferation after vascular injury seems warranted.
Time Relation
As in animal experiments, no major difference in inhibition of neointimal proliferation was observed whether the drug was given 1 hour before or within 2 days after the wall injury. It was assumed that ACE inhibition by cilazapril could be started immediately after PTCA. 30 In experimental studies, the strongest inhibition of neointima formation was obtained when treatment was started 6 days before injury. It could be that a period of drug impregnation before injury might be required to obtain an inhibitory effect, although a significant but slightly attenuated effect was observed when it was started 2 days after injury.
Species Relation
Powell et a146 compared the effects of high doses of cilazapril (10 mg/kg/day) and captopril (100 mg/kg/day) on neointimal proliferation in the rat carotid artery model. Both agents were highly effective and, in addition, concomitant heparin therapy appeared to exert a synergistic antiproliferative effect. Similarly, in the atherosclerotic rabbit iliac model, cilazapril (5 mg/kg/day) reduced the incidence of restenosis after balloon injury. 50 
Relevance of Mechanism ofAction
The most recent theory on restenosis put forward by Lindner and Reidy12 indicates that bFGF released after disruption and cell necrosis of the endothelium and media is the factor that initiates the proliferation and duplication of the smooth muscle cells. These subsequently activated smooth muscle cells tend to migrate in the subintima of the vessel, where they are attracted by the PDGF stemming from the aggregated platelets: It is in this location and stage that angiotensin II acts on them as a comitogen. This complex interaction may be the predominant biological scenario in certain species such as rat and rabbit but may be inoperative in other species such as the baboon and guinea pig.
Recently, Forrester et a117 hypothesized that restenosis is a manifestation of the general wound-healing process expressed specifically in vascular tissue. They list five different groups of growth factors: PDGF, FGF, EGF (epidermal growth factor), IGF (insulin-like growth factor), and TGF (transforming growth factor), each with a specific role and with possibly many interactions. It is of course possible that angiotensin II has only a minor role in this complex process and that ACE inhibition did not result in less angiographic restenosis.
In contrast, Schwartz et a157 hypothesize that mural thrombus is the most important factor in the restenosis process: It is seen in all treated animals after injury; after 3 days it is covered by endothelium, and later on, smooth muscle cells start to grow downward toward the media, suggesting that neointimal cells are probably not
Conclusions
Long-term ACE inhibition with cilazapril in a dose of 5 mg b.i.d. does not prevent restenosis and does not favorably influence the overall clinical outcome after PTCA in patients. The results of the MARCATOR trial must be awaited to see whether a higher dose of cilazapril has any effect on angiographic restenosis.
